Recently, K. He at al. targeted STAT6 by ASO approach along with hypofractionated radiotherapy to primary tumors in three bilateral murine NSCLC models (Lewis lung carcinoma, 344SQ-parental, and anti-PD-1-resistant 344SQ lung adenocarcinomas). This evidence concerns the gene STAT6 and non-small cell lung carcinoma.